Last update 21 Dec 2024

Flotegatide-F18

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms
Flotegatide F18, RGD F18, RGD-F18
Target
αvβ3
Mechanism
αvβ3 stimulants(Integrin alpha-V/beta-3 stimulants), PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
NeoplasmsNervous System DiseasesCardiovascular Diseases+ [3]
Active Indication-
Inactive Indication
AtherosclerosisBreast CancerCarotid Stenosis+ [6]
Originator Organization
Siemens Healthineers AGSiemens Healthineers AG
Active Organization-
Inactive Organization
Siemens Molecular Imaging, Inc.Assistance Publique des Hôpitaux de Paris SAAssistance Publique des Hôpitaux de Paris SA
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC41H60FN13O13
InChIKeySDQRGILXNZSUMD-ABRGNQFASA-N
CAS Registry1010702-75-6

Related

1
Clinical Trials associated with Flotegatide-F18
NCT02325349 / TerminatedPhase 2IIT
PET/CT Molecular Imaging of Angiogenesis in Pulmonary or Head and Neck Cancers Prior to or During Chemotherapy Including Agent With Antiangiogenic Effect. A Prospective Multicentric Study of Efficacy and Tolerability.
100 Clinical Results associated with Flotegatide-F18
Login to view more data
100 Translational Medicine associated with Flotegatide-F18
Login to view more data
100 Patents (Medical) associated with Flotegatide-F18
Login to view more data
100 Deals associated with Flotegatide-F18
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Carotid StenosisPhase 2
US
Siemens Molecular Imaging, Inc.
01 May 2012
Breast CancerPhase 2
US
Siemens Molecular Imaging, Inc.
01 Sep 2009
Colorectal CancerPhase 2
US
Siemens Molecular Imaging, Inc.
01 Sep 2009
Non-Small Cell Lung CancerPhase 2
US
Siemens Molecular Imaging, Inc.
01 Sep 2009
NeoplasmsPhase 2
FR
Assistance Publique des Hôpitaux de Paris SAAssistance Publique des Hôpitaux de Paris SA
-
GliomaPhase 1
US
Siemens Molecular Imaging, Inc.
01 Aug 2008
MelanomaPhase 1
US
Siemens Molecular Imaging, Inc.
01 Aug 2008
SarcomaPhase 1
US
Siemens Molecular Imaging, Inc.
01 Aug 2008
AtherosclerosisPreclinical
US
Siemens Molecular Imaging, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free